Nephrology

Non-Hispanic Black and Hispanic children were less likely to undergo preemptive KT and had longer wait times than non-Hispanic White children.

Findings from the HOPE Consortium Trial suggest PCST can help pain interference and quality of life in patients on hemodialysis experiencing chronic pain.

The month in review features coverage of renal pipeline updates, a new nephrology podcast episode, and recent research in IgAN and FSGS.

Study findings suggest outcomes observed with intensive blood pressure targets in SPRINT are transportable to patients with CKD in clinical practice.

Systematic review findings point to bias and insufficient clinical applicability with current mortality risk models in patients with kidney failure.

Patients hospitalized for severe COVID-19 had an accelerated eGFR decline relative to those with pneumonia due to other infections.

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

Gestational exposure to certain NSAIDs during different trimesters of pregnancy was associated with an increased risk of childhood CKD.

The FDA's decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.

Study findings suggest the potential utility of ΔADC for assisting the clinical, pathological, and prognostic risk stratification of patients with IgAN.

Despite having a lower risk of hospitalization, cardiovascular events, and mortality, patients with IgAN and FSGS had a higher risk of CKD progression.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

As announced by NovelMed on December 2, 2024, the FDA has granted IND clearance for Ruxoprubart to commence an efficacy trial for the treatment of IgAN.

Initiation of population-wide CKD screening followed by conventional CKD treatment plus SGLT2 inhibitors at 55 years of age was cost-effective.

Treatment with the novel selective endothelin receptor type A antagonist alongside standard care reduced UPCR in patients with IgAN in a phase 2 trial.

The study is one of the first to report United States IgAN incidence based on a large racially and ethnically diverse cohort.

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.

In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.

Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.

Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.

Carla Nester, MD, discusses her perspective on the APPEAR-C3G 12-month data from ASN Kidney Week 2024.

The APPEAR-C3G trial’s 12-month data show Novartis’ iptacopan significantly reduced proteinuria in C3G, with sustained renal improvements and stable eGFR.